Stoke Therapeutics, Inc. (FRA:0GT)

Market Cap	1.53B +220.8%
Revenue (ttm)	27.82M -83.2%
Net Income	-147.24M
EPS	-2.43
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	24.23
Previous Close	25.67
Day's Range	24.23 - 24.23
52-Week Range	8.30 - 32.80
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2026

About Stoke Therapeutics

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome i...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Employees: 170
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 0GT

Financial Performance

In 2025, Stoke Therapeutics's revenue was $184.42 million, an increase of 404.50% compared to the previous year's $36.56 million. Losses were -$6.89 million, -92.26% less than in 2024.

Financial numbers in USD